These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35741847)

  • 1. Prevalence of Pathogenic Germline
    Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
    Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first Japanese nationwide multicenter study of
    Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
    Rust K; Spiliopoulou P; Tang CY; Bell C; Stirling D; Phang T; Davidson R; Mackean M; Nussey F; Glasspool RM; Reed NS; Sadozye A; Porteous M; McGoldrick T; Ferguson M; Miedzybrodzka Z; McNeish IA; Gourley C
    BJOG; 2018 Oct; 125(11):1451-1458. PubMed ID: 29460478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
    Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N
    Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
    Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
    Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
    Yoshihara K; Enomoto T; Aoki D; Watanabe Y; Kigawa J; Takeshima N; Inomata H; Hattori K; Jinushi M; Tsuda H; Sugiyama T
    Cancer Sci; 2020 Sep; 111(9):3350-3358. PubMed ID: 32495382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the likelihood of a
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
    J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
    Hu-Heimgartner K; Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Vazquez C; Friedlaender A; Vuilleumier A; Bodmer A; Viassolo V; Sandoval JL; Chappuis PO; Labidi-Galy SI
    Fam Cancer; 2023 Jul; 22(3):283-289. PubMed ID: 37119509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
    BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.
    Sekine M; Enomoto T; Arai M; Yokoyama S; Nomura H; Nishino K; Ikeuchi T; Kuriyama Y; Nakamura S;
    J Hum Genet; 2022 May; 67(5):267-272. PubMed ID: 34983974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
    BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Lanjouw L; Mourits MJE; Bart J; Ter Elst A; Berger LPV; van der Hout AH; Alam N; de Bock GH
    Int J Gynecol Cancer; 2023 Aug; 33(8):1260-1269. PubMed ID: 37137525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
    Park S; Lee E; Park S; Lee S; Nam SJ; Kim SW; Lee JE; Yu JH; Kim JY; Ahn JS; Im YH; Park WY; Park K; Park YH
    Mol Cancer Res; 2020 Sep; 18(9):1315-1325. PubMed ID: 32554602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
    Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
    Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation.
    Kim JW; Kang HE; Choi J; Yun SG; Jung SP; Bae SY; You JY; Choi YJ; Kim YH; Park KH
    Cancer Res Treat; 2023 Jan; 55(1):155-166. PubMed ID: 35681111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.
    Matta BP; Gomes R; Mattos D; Olicio R; Nascimento CM; Ferreira GM; Brant AC; Boroni M; Furtado C; Lima V; Moreira MÂM; Dos Santos ACE
    Sci Rep; 2022 Nov; 12(1):18629. PubMed ID: 36329109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.